Walsh JA, Magrey MN, Baraliakos X, et al. - The impact of ixekizumab on self‐reported functioning and health was evaluated in patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA). Individuals were assigned randomly in 1:1:1 ratio to receive subcutaneous 80 mg ixekizumab every 4 weeks or every 2 weeks, or placebo for 52 Weeks. Self‐reported functioning and health endpoints included the Medical Outcomes Study 36‐Item Short-Form Health Survey 36‐item, Assessment of SpondyloArthritis international Society Health Index, and European Quality of Life‐5 Dimensions‐5 Level health‐utility. It was shown that in patients with nr‐axSpA, ixekizumab was superior to placebo improving self‐reported functioning and health at Weeks 16 and 52.